A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy-Reference-Cited by-同舟云学术

A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy

Published:2006-10 Issue:10 Volume:8 Page:761-763
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Escalante Sonia Maciá,Lescure Álvaro Rodríguez,Sanz Vanesa Pons,Banaclocha Natividad Martínez,Ponce Carmen Guillén,Mena Alfredo Carrato

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-006-0125-6.pdf

Reference4 articles.

1. Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neuoverexpressing metastatic breast cancer. Am J Ther. 2005;12(3):243–53.

2. De Laurentiis M, Cancello G, Zinno L, et al. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Ann Oncol. 2005;16 Suppl 4:S7–13.

3. Luftner D, Pollmann D, Schildhauer S, et al. Perspectives of immunotherapy in metastatic breast cancer. Anticancer Res. 2005;25(6C):4599–604.

4. Rossi A, Colantuoni G, Cantore N, et al. Complete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case. Anticancer Res. 2004;24(1):317–9.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?;Annals of Hepatology;2018-11

2. Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series;International Journal of Surgery Case Reports;2018

3. Complete response after docetaxel plus pertuzumab plus trastuzumab chemotherapy for multimetastatic positive Her-2 breast cancer;EUR J GYNAECOL ONCOL;2018

4. Long‑responders to anti‑HER2 therapies: Aï¿½caseï¿½report and review of the literature;Molecular and Clinical Oncology;2017-11-08

5. Duration of Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer in Prolonged Remission;Current Oncology;2016-04-01